Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06252616 In Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2022
Price :
$35
*
At a glance
- Drugs Domagrozumab (Primary) ; Domagrozumab (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 14 Sep 2022 Data from this study and other phase 2 study (NCT02310763) was sought to establish the PK/PD relationship between free domagrozumab and total myostatin concentrations in pediatric patients with DMD using a prior semi-mechanistic model, published in the Clinical Pharmacology and Therapeutics
- 12 Mar 2016 Population pharmacokinetic/pharmacodynamic model results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 24 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.